The transactions highlighted below are representative of Greenhill engagements. In addition, the Firm has completed many engagements that were not publicly-disclosed.
Recent Transactions
Sort By
29-Jan-24
$4.8 billion
Target:
Digicel Group
Advised PGIM, Contrarian Capital Management, and GoldenTree Asset Management on the restructuring of Digicel Group, a communications and entertainment provider with operations in 25 Caribbean and Central American markets
29-Mar-23
Undisclosed
Target:
Scandinavian Enviro Systems AB
Acquiror:
Antin Infrastructure Partners
Advising Enviro on the creation of the world’s first large-scale tire recycling group in a JV with Antin Infrastructure Partners, supported by Michelin
30-Dec-22
$153 million
Target:
Annovera®, Imvexxy®, Bijuva®, and prescription prenatal vitamin products
Acquiror:
Mayne Pharma
Advised TherapeuticsMD, Inc., an innovative, leading women’s healthcare company on definitive agreements to license its products to Mayne Pharma
13-Oct-22
$47 million
Target:
Electro Optic Systems
Acquiror:
Washington H. Soul Pattinson
Advised Electro Optic Systems, an Australian founded and listed aerospace and defence company, on agreeing financing terms with its largest shareholder, Washington H. Soul Pattinson
02-Sep-22
Pending
$205 million
Target:
brsk
Acquiror:
Ares Management
Advising brsk, a UK-based alternative network broadband provider, on its first debt-raise of £178m from Ares Management, a leading global alternative investment manager
08-Apr-22
$364 million
Target:
Netomnia
Acquiror:
DigitalBridge Investment Management, Advencap, SoHo Square
Advised Netomnia, a leading UK-based fiber operator, on its £295m fundraise led by DigitalBridge Investment Management with follow-on commitments from existing shareholders Soho Square Capital LLP and Advencap Limited
17-Dec-21
N.A.
Target:
MRO Holdings, Inc. (Panama)
Acquiror:
N.A.
Advised MRO Holdings, a leading airframe maintenance, repair and overhaul (“MRO”) services provider in the Americas, on its term loan financing
15-Nov-21
$166 million
Target:
Netomnia
Acquiror:
Avenue Capital, Advencap
Advised Netomnia, a UK-based fibre operator, on its first large-scale fundraise of £123m
09-Sep-21
$2.1 billion
Target:
easyJet plc
Acquiror:
N/A
Advising and acting as joint sponsor to UK-based easyJet plc, a leading low-cost European airline carrier, on its £1.2bn fully underwritten rights issue & $400m secured RCF
09-Jun-21
$310 million
Target:
Australian Unity Funds Management
Acquiror:
N/A
Advised Australian Unity Funds Management on a A$320m equity raising and A$80m cash liquidity offer for Australian Unity Healthcare Property Trust
11-Mar-21
$2.1 billion
Target:
Education Australia’s 40% Stake in IDP Education
Acquiror:
Education Australia’s 38 University Shareholders
Advising ASX-listed IDP Education on the restructure of Education Australia’s 40% ownership stake in the business
11-Mar-21
$725 million
Target:
Speedcast International Limited
Acquiror:
Centerbridge Partners L.P.
Advised the Ad Hoc Group of First Lien Lenders on the Chapter 11 restructuring of Speedcast International Limited (ASX:SDA)
19-Feb-21
$33 million
Target:
Acacia Pharma Group plc
Acquiror:
N/A
Advised Acacia Pharma Group plc, a US headquartered commercial stage biopharmaceutical company incorporated in England and listed in Belgium, on its placing of 10m new ordinary shares at a price of €2.70 per share
01-Oct-20
$2.6 billion
Target:
Rolls-Royce £2bn Fully Underwritten Rights Issue
Acquiror:
N/A
Advising Rolls-Royce on its Fully Underwritten £2bn Rights Issue, as part of a broader recapitalisation package
29-Sep-20
$200 million
Target:
Travel & Transport
Acquiror:
Corporate Travel Management
Advising Corporate Travel Management on its acquisition of US-based travel management company Travel & Transport and the associated A$375mm equity raise
10-Sep-20
$195 million
Target:
Saga plc
Acquiror:
Sir Roger De Haan
Advised Sir Roger De Haan on his cornerstone investment of £100mm in Saga, the UK provider of products and services exclusively for the over 50s, as part of its £150m equity raise
12-Nov-18
$84 million
Target:
AUB Group Limited
Advised ASX-listed AUB Group, a leading insurance intermediary business operating a network of over 100 insurance brokers and underwriting agencies across Australia and New Zealand, on its fully underwritten entitlement offer to raise A$116mm
28-Sep-18
$NA
Target:
Blue Sky Alternative Investments Limited
Acquiror:
Oaktree Capital Management L.P.
Advised Blue Sky, an ASX-listed diversified alternative assets manager, on its response to an activist short-seller campaign, strategic review of recapitalisation options, and receipt of a A$50mm long-term capital investment by Oaktree via a 7-year senior secured convertible loan note facility
28-Sep-18
$NA
Target:
Grupo Monge
Advised Grupo Monge, a leading Latin American retailer and consumer finance company, in the establishment of a long-term funding relationship with impact investment manager BlueOrchard
10-Jul-18
$1.1 billion
Target:
The AA plc
Advised the AA plc, the UK’s largest roadside assistance provider, on the refinancing of £825mm of its senior secured facilities
02-May-18
$3.7 billion
Target:
Concordia International Corp.
Advised an Ad Hoc Group of Cross-over Debtholders on Concordia International’s cross-border Canadian restructuring and recapitalization, including a US$586.5mm common equity private placement, the equitization of ~US$1.7bn of unsecured debt and the partial paydown and exchange of ~US$2.2bn of secured debt
31-Oct-17
$2.0 billion
Target:
Hirslanden Private Hospital Group
Advised Hirslanden Private Hospital Group, Switzerland's largest private hospital group and a wholly-owned subsidiary of Mediclinic International Plc, on the refinancing of its CHF 2.0 billion senior secured bank debt
04-Oct-16
$223 million
Target:
US rights to Toprol-XL (AstraZeneca)
Acquiror:
Aralez Pharmaceuticals Inc.
Advised Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company in connection with the financing of its acquisition of the US rights to cardiovascular drug Toprol-XL (metoprolol succinate) and its Authorized Generic from AstraZeneca.
09-Aug-16
$NA
Target:
Bionomics Limited
Advised ASX-listed Bionomics, a clinical stage biopharmaceutical company focused on the treatment of serious central nervous system disorders and cancer, on a consultation process with shareholders following calls for Board change, leading to the formation of a shareholder working group of leading institutional investors and company-led Board renewal.
19-Jan-16
$NA
Target:
Recepta Biopharma
Acquiror:
Inova Empresa Fundo de Investimento em Participações
Advised Recepta Biopharma on a capital raise